electroCore Q2 2026 Earnings: Revenue Rises 28% as Net Loss Narrows

electroCore (Nasdaq: ECOR) reported Q2 2026 net sales of $9.45 million, up approximately 28% from $7.38 million a year earlier, while GAAP diluted loss per share improved to $0.33 from $0.44. Higher VA sales of Rx gammaCore and Quell, together with Truvaga growth, increased gross profit and narrowed both the GAAP net loss and adjusted EBITDA loss.

Core Earnings Results

Revenue growth for the quarter ended June 30 was primarily driven by Quell Fibromyalgia and Rx gammaCore products sold through the Department of Veterans Affairs, as well as nonprescription Truvaga products. The resulting increase in gross profit more than offset the rise in operating expenses, reducing the operating and net losses.

Gross margin declined because of a higher inventory reserve, preventing the 28% revenue increase from producing an equivalent improvement in profitability.

Adjusted EBITDA is a non-GAAP measure defined by the company. Among other items, the Q2 2026 calculation excluded $755,000 of stock-based compensation.

Business and Channel Performance

U.S. prescription sales remained electroCore’s largest channel, reaching $7.45 million and accounting for most of the company’s quarterly revenue. General Wellness was the second-fastest-growing reported channel.

Quell sales reached $1.3 million, increasing approximately 700% year over year and 30% from Q1 2026. Cumulative Quell revenue since the May 2025 acquisition from NeuroMetrix was approximately $4.0 million, including $3.8 million of Quell Fibromyalgia sales into the VA.

Prescription gammaCore revenue increased approximately 11% year over year. About 16,400 VA patients have received a gammaCore device, representing approximately 2.7% penetration of the company’s estimated addressable VA headache market.

Truvaga revenue increased approximately 27% year over year to $1.3 million but declined 17% sequentially. electroCore reduced Truvaga spending in response to higher media prices.

Commercial restructuring targets lower selling costs

The company doubled its sales regions from three to six and recruited, contracted, and trained 17 new independent representatives. The smaller territories are intended to increase accountability for new-patient acquisition and refill rates while diversifying sales across more VA accounts.

electroCore also redesigned its incentive plan. Management expects variable incentive compensation to decline from approximately 35% of prescription revenue to 27% and targets sales and marketing expense equal to 54% of revenue by the end of 2027.

Lovell Government Services will become the primary Federal Supply Schedule contract holder for electroCore products across VA and Department of Defense markets. The company expects this arrangement to simplify federal procurement and eliminate transaction fees equal to roughly 3% of general and administrative expense associated with direct sales. These savings are targets rather than benefits already reflected in the quarter.

Profitability, Liquidity, and Balance Sheet

Research and development expense increased to $818,000 from $511,000, primarily because of additional studies and grants, higher stock-based compensation, and initial development costs for enhancements to the Truvaga mobile application.

Selling, general and administrative expense rose to $10.13 million from $9.44 million. Sales and marketing expense increased by $1.4 million, including approximately $900,000 of variable costs supporting the $2.1 million increase in net sales. General and administrative expense declined by $700,000, helped by the absence of a $500,000 TAC-STIM bad-debt charge recorded in Q2 2025 and lower professional fees.

Cash and cash equivalents were $8.50 million at June 30, up from $7.04 million at the end of 2025, but marketable securities declined to $1.54 million from $4.58 million. As a result, combined cash, cash equivalents, and marketable securities decreased to approximately $10.0 million from $11.6 million.

Total assets were $17.06 million, compared with total liabilities of $19.85 million. The stockholders’ deficit widened to $2.79 million from $1.71 million at December 31, 2025.

Earnings Guidance

The company raised its full-year 2026 revenue outlook to growth of more than 30% over 2025, although the release did not provide the previous quantitative target. It also expects to reach positive adjusted EBITDA in Q3 2027.

The adjusted EBITDA outlook is non-GAAP. electroCore did not provide a corresponding GAAP reconciliation because it said the timing and size of certain reconciling items could not be reasonably predicted.

Recent Insider Transactions

The supplied insider data reports 167,055 shares purchased and 105,739 shares sold during the previous six months, resulting in net purchases of 61,316 shares across eight purchase and sale transactions. Total insider holdings were listed at 2.69 million shares; these figures do not establish the insiders’ views about the company’s outlook.

The ten most recent reported records include open-market purchases and sales, stock awards, and a derivative-security transaction.

Risks Investors Should Watch

• Continuing losses and liquidity needs: electroCore remained unprofitable, combined cash and marketable securities declined from year-end, and the company reported a stockholders’ deficit. Its disclosures identify the ability to raise additional capital and continue as a going concern as risks.
• Dependence on federal channels: The VA was the largest growth driver, and electroCore intends to generate most of its remaining 2026 sales in that channel through Lovell. Execution or procurement issues could therefore affect growth.
• Unproven cost savings: Lower incentive compensation and transaction fees are management targets. The anticipated benefits from the sales restructuring and Lovell arrangement may not materialize on schedule or at the expected level.
• Margin and marketing pressure: Gross margin declined because of a larger inventory reserve, while higher media prices led electroCore to reduce Truvaga spending as that product’s revenue fell sequentially.
• Quell-related regulatory exposure: Quell has become a meaningful growth contributor, while the company identifies FDA regulatory matters affecting the product line as a potential risk.

Summary

Q2 2026 combined VA-led revenue growth with narrower GAAP and adjusted EBITDA losses, even as gross margin declined and operating spending increased. Quell, Rx gammaCore, and Truvaga were the principal sales drivers. Future progress depends on sustaining federal-channel growth, delivering the planned commercial cost reductions, managing liquidity, and moving toward the company’s Q3 2027 adjusted EBITDA profitability target.